- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 19
- States / cities
- Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,771
matching trials from the live ClinicalTrials.gov search.
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity
- Interventions
- Virtual Group Visit
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Orland Park, Illinois
- Conditions
- Diet, Healthy, HbA1c, Blood Pressure
- Interventions
- Medically Tailored Meals and Nutritional Counseling, Cardiovascular Health Promotion Educational Program
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
- Interventions
- None (Observational)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- placebo, Exenatide LAR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 7
- States / cities
- Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Fenofibrate
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 30 Days and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2045
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Drug
- Lead sponsor
- Metabolic Solutions Development Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more
- Conditions
- Type II Diabetes Mellitus
- Interventions
- MI- informed SMS program
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- Fabla Mobile App
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
- Interventions
- Colesevelam HCl
- Drug
- Lead sponsor
- KineMed
- Industry
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0519-0130, Placebo, Trizepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Chula Vista, California • Fresno, California • Inglewood, California + 46 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more
- Conditions
- Type2 Diabetes
- Interventions
- Abbott Freestyle Libre Pro, LifeStyle
- Device · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes
- Interventions
- Telephonic Diabetes Self-Management Support, Educational Print Materials
- Behavioral · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Muraglitazar, Pioglitazone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1362885, Glucagon, Glucagon + GSK1362885
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- Bydureon, placebo
- Drug
- Lead sponsor
- Phoenix VA Health Care System
- Federal
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Obesity, Type 2 Diabetes Mellitus in Obese
- Interventions
- K-757 and K-833, Matching placebo to K-757 and K-833
- Drug
- Lead sponsor
- Kallyope Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
- Interventions
- MODI Algorithm
- Device
- Lead sponsor
- DreaMed Diabetes
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Ruboxistaurin mesylate
- Drug
- Lead sponsor
- Chromaderm, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 13
- States / cities
- Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
- Conditions
- Insulin Resistance, Polycystic Ovary Syndrome, Hyperinsulinism, Obesity, Metabolic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Ali Chappell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas